BeiGene(BGNE) - 2024 Q4 - Annual Results

Financial Performance - Fourth quarter 2024 net product revenues reached $1.1 billion, a 77% increase from$ 630 million in Q4 2023; full year revenues totaled $3.8 billion, up 73% from$ 2.2 billion in 2023[4] - Global BRUKINSA revenues for Q4 2024 were $828 million, a 100% increase year-over-year; full year revenues were$ 2.6 billion, reflecting a 105% growth compared to 2023[6] - Total revenue for Q4 2024 was $1.1 billion, a 78% increase from$ 634 million in Q4 2023; full year total revenue was $3.8 billion, up 55% from$ 2.5 billion in 2023[4] - BRUKINSA sales in the U.S. totaled $616 million in Q4 2024, a 97% increase year-over-year; full year sales were$ 2.0 billion, reflecting a 106% growth[10] - Tislelizumab sales reached $154 million in Q4 2024, a 20% increase from the prior year; full year sales were$ 621 million, up 16% compared to 2023[11] - Product revenue reached $1.1 billion for Q4 2024 and$ 3.8 billion for the full year, up from $631 million and$ 2.2 billion in the prior-year periods, driven primarily by increased sales of BRUKINSA[27] Operational Efficiency - GAAP loss from operations narrowed to $79.4 million in Q4 2024, a 79% improvement from a loss of$ 383.8 million in Q4 2023; full year GAAP loss was $568.2 million, down 53% from$ 1.2 billion in 2023[4] - Adjusted income from operations for Q4 2024 was $78.6 million, a 129% increase from a loss of$ 267.2 million in Q4 2023; full year adjusted income was $45.4 million, a 106% improvement from a loss of$ 752.5 million in 2023[4] - Net loss per share improved to $0.11 for Q4 2024 from$ 0.27 in the prior-year period, with a full-year net loss per share of $0.47 compared to$ 0.65[31] - Adjusted income from operations for the full year 2024 was $45,356, compared to a loss of$ (752,473) in 2023, indicating improved operational efficiency[48] Future Guidance - Full year 2025 revenue guidance is projected between $4.9 billion and$ 5.3 billion, with anticipated positive GAAP operating income and cash flow generation[6] - Full year 2025 revenue guidance is set between $4.9 billion and$ 5.3 billion, reflecting strong growth expectations for BRUKINSA[34] - GAAP operating expenses for FY 2025 are projected to be between $4.1 billion and$ 4.4 billion, with a gross margin percentage expected in the mid-80% range[35] Research and Development - The company advanced six New Molecular Entities (NMEs) into the clinic in Q4 2024, with a total of 13 NMEs advanced for the full year[6] - Research and development expenses for FY 2024 totaled $1.95 billion, a 10% increase from the prior year, driven by advancing clinical programs[29] - Adjusted research and development expenses for Q4 2024 were$ 474,874, an increase of 8.5% from $437,383 in Q4 2023[48] Cash Flow and Assets - Cash provided by operations for Q4 2024 was$ 75 million, an increase of $297 million year-over-year, while cash used in operations for the full year decreased by$ 1.0 billion[32] - Total assets as of December 31, 2024, were $5.92 billion, with total liabilities of$ 2.59 billion and total equity of $3.33 billion[44] - Cash, cash equivalents, and restricted cash at the end of Q4 2024 were$ 2,638,747, down from $3,185,984 in Q4 2023, representing a decrease of 17.1%[46] - Net cash provided by operating activities in Q4 2024 was$ 75,160, compared to a net cash used of $(221,638) in Q4 2023, indicating a significant turnaround[46] - The company reported a net decrease in cash, cash equivalents, and restricted cash of$ (74,681) in Q4 2024, contrasting with an increase of $105,092 in Q4 2023[46] Operating Expenses - Total operating expenses for Q4 2024 were$ 1.05 billion, a 15% increase from $912 million in Q4 2023, with R&D expenses rising by 10% and SG&A expenses increasing by 21%[29] - GAAP cost of sales for products in Q4 2024 was$ 160,560, up 51.8% from $105,832 in Q4 2023[48] - Adjusted operating expenses for the full year 2024 were$ 3,218,232, up 13.1% from $2,843,649 in 2023[48] Corporate Changes - The company plans to change its name to BeOne Medicines Ltd. and has changed its Nasdaq ticker from "BGNE" to "ONC" pending shareholder approval[25] - The company plans to continue investing in the global commercial launch of BRUKINSA, particularly in the U.S. and Europe, with SG&A expenses as a percentage of product sales decreasing significantly[30]